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Abstract: In the last year, the armamentarium of melanoma therapeutics has radically changed. 
Recent discoveries in melanoma biology and immunology have led to novel therapeutics   targeting 
known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents 
have reported measurable and meaningful benefits to patients with metastatic disease. In this 
article, we review recent findings and discuss their significance in melanoma therapy. As our 
understanding of melanoma biology grows, this initial therapeutic success may be enhanced 
through the use of molecular markers to select patients, and new targeted immunotherapies in 
sequential or combination drug regimens.
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Epidemiology and treatment of metastatic 
melanoma
Malignant melanoma is an important health care issue. The incidence of melanoma 
has increased dramatically over the last four decades and melanoma is now one of 
the most common forms of cancer. In 2011, over 75,000 North Americans will be 
diagnosed with melanoma and over 9000 will die from it.1,2 Although less common 
than cancers of the breast, prostate, or colon, it is potentially more lethal. It has a high 
propensity for hematogenous and lymphatic dissemination to regional and distant 
sites and is poorly responsive to most systemic therapies. The 5-year survival rate for 
metastatic melanoma is dismal, ranging from 5% to 10% with a median survival of 
less than 8 months with treatment.3
Until recently, the therapeutic options for patients with metastatic melanoma were 
limited. The only approved treatment options were dacarbazine and interleukin 2 (IL-2). 
Dacarbazine, an alkylating agent, has a response rate of ,10%, with median response 
durations of 4–8 months.4 Single-agent therapy with IL-2, an immune-modulatory 
agent, has similar overall response rates of 16%, with ∼5% of patients achieving durable 
complete responses (CRs) that may result in long-term survival in selected patients.5 
Use of IL-2 is limited by its low overall response rate and its potential severe multiorgan 
toxicities requiring management in specialized cancer centers. With these agents, 
remissions are infrequent, usually of short duration, and treatment is primarily palliative, 
as neither agent has been shown definitively to improve  survival. Improved treatments 
with high-risk resected and advanced metastatic disease are urgently needed.
In the last year, there have been major treatment advances for metastatic 
melanoma patients. Two agents, ipilimumab (Yervoy™, Bristol-Myers Squibb, 
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  Princeton, NJ) and vemurafenib (Zelboraf, Plexxikon/Roche, 
Auckland, NZ), have demonstrated improved survival in 
patients with advanced melanoma when compared with stan-
dard   treatments. The clinical benefits of these targeted drugs 
have been realized after decades of research in the molecular 
pathogenesis of melanoma. This research has identified 
tumor and immune cellular signaling pathway abnormali-
ties that promote melanoma development and progression. 
Once regarded as a cancer with a dismal record of negative 
Phase III treatment trials, melanoma is now a tumor type 
for the clinical evaluation of paradigm-shifting therapeutic 
  strategies. In this review, we outline key molecular pathways 
and the agents targeting them.
Melanoma, the immune system, 
and immune targeting monoclonal 
antibodies
There is overwhelming evidence that melanoma is an 
immune-responsive cancer. Spontaneous regression of mela-
noma is observed and is probably due to immune   processes. 
The identification of tumor-infiltrating lymphocytes and 
melanoma antigen-specific T-cells in peripheral blood from 
cancer patients are evidence that melanoma-specific immune 
recognition and activation occur.6–8 Moreover, melanoma 
exhibits cellular properties that can be explained by immune 
selection, such as downregulation of major histocompat-
ibility complex class I expression or release of cytokines 
such as transforming growth factor-beta.9,10 Lastly, dramatic 
clinical responses have been demonstrated with immune-
modulatory treatments, such as IL-2 and adoptive T-cell 
transfer in selected patients with metastatic melanoma, 
although neither of these treatments have demonstrated 
superiority over standard of care in randomized clinical 
trials.4,11 However, ipilimumab, a novel monoclonal antibody 
modulating the immune system, provides the first evidence 
that an immunotherapy strategy can change the clinical 
course of metastatic melanoma and result in improvement 
in patient survival.12,13
Ipilimumab is a modulator of immune system   activation. 
T-cell activation occurs when an antigen is presented 
by a major histocompatibility complex molecule and a 
co-stimulatory molecule, B7.1 or B7.2, binds to CD28.14 
Simultaneously, downregulation of this process is initi-
ated by B7-cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) binding. Inhibitory co-receptors and pathways 
restrict T-cell functions to prevent autoimmunity. In 
  cancer patients, this restraint impedes antitumor immunity. 
Monoclonal   antibodies that bind to CTLA-4 and block the 
interaction between B7 and CTLA-4 inhibit this negative 
signal, and may break peripheral tolerance to self-tissues 
and induce antitumor responses. Ipilimumab is a fully 
human, IgG1 monoclonal antibody that blocks CTLA-4. By 
inhibiting CTLA-4, ipilimumab potentiates T-cell activation 
and proliferation, promoting antitumor immunity. Proof of 
benefit from the approach is found in two recent random-
ized controlled Phase III trials that demonstrated improved 
survival in patients with metastatic melanoma treated with 
ipilimumab.12,13 However, the drug’s effect on the immune 
response is not tumor specific: ipilimumab treatment has been 
associated with severe and potentially fatal immunological 
adverse effects due to T-cell activation and proliferation. 
A risk evaluation and mitigation strategy has been set up to 
inform prescribers of the potential risks.
The first ipilimumab Phase III study randomized patients 
with advanced stage melanoma who progressed on standard 
treatments, to receive ipilimumab plus gp100 (a melanoma-
specific antigen), ipilimumab alone, or gp100 alone.12 The 
median overall survival (OS) was statistically superior among 
patients randomized to an arm containing ipilimumab, as 
compared with those patients receiving gp100 alone (approxi-
mately 10 months versus 6.4 months). No difference in OS 
was detected between the ipilimumab groups. This was the 
first study to demonstrate a survival benefit in the setting of 
advanced melanoma in over three decades, but the enthu-
siasm was tempered by the lack of a standard treatment in 
the control arm.
The second Phase III study, conducted in previously 
untreated metastatic melanoma patients and with an accept-
able control treatment arm, corroborated the benefits observed 
with ipilimumab treatment.13 This study randomly assigned 
patients with previously untreated metastatic melanoma to 
ipilimumab plus dacarbazine or placebo plus dacarbazine. 
OS was significantly longer in the group receiving ipilimumab 
plus dacarbazine than in the group receiving dacarbazine alone: 
11.2 months versus 9.1 months, respectively.   Interestingly, 
benefit from ipilimumab was seen across patient subgroups 
based on human leukocyte antigen types, tumor mutations, 
or prognostic factors such as serum lactate dehydrogenase. 
This confirmed the clinical benefit of ipilimumab and added 
to the growing number of immunotherapeutic strategies for 
patients with advanced melanoma.
These ipilimumab trials demonstrated proof of clinical 
benefit of immune modulation in metastatic melanoma. 
Key areas for future research focus on improving the 
risk–benefit of immunotherapy in metastatic disease and 
evaluating the agent in high-risk early stage disease. For the 
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former, efforts focused on the following areas are required: 
(1) reduction in the frequency and severity and improved 
management of adverse effects, (2) identification of markers 
of tumor sensitivity and patient risk of severe side effects, 
and (3) the evaluation of combination strategies that either 
increase the tumor-specific immune response and/or target 
tumor proliferation and survival pathways. For the latter, 
trials are underway to evaluate the benefit of ipilimumab 
in resected melanoma patients. Agents and trial results of 
therapies targeting the immune system are summarized in 
Table 1. Tumor-targeting drugs are discussed further in the 
next section.
The molecular pathways altered  
in melanoma cells
Crucial genetic alterations that enhance the oncogenic 
potential in melanoma have been identified. Key muta-
tions that lead to constitutive activation of tumor growth 
and survival pathways occur in the receptor tyrosine kinase 
CKIT (CD117), and the RAS/RAF/MEK/ERK and phos-
phoinositide-3-OH kinase (PI3K)/Protein Kinase B (AKT)/
phosphatase and tensin homolog deleted on chromosome 10 
(PTEN) signal transduction systems (Figure 1). Although 
convenient to conceptualize these pathways as independent, 
significant interactions occur and simultaneous activation 
of the pathways plays a role in melanoma pathogenesis. The 
demonstration that the mutant BRAF inhibitor vemurafenib 
improves survival in patients with metastatic melanoma 
proves that targeting aberrant proteins of signaling pathways 
with kinase inhibitors can lead to clinical benefit.15 Below, we 
describe some of these key pathways and the agents designed 
to target the components of these pathways (see Figure 1).
The RAS/RAF/MEK/ERK pathway
The RAS/RAF/MEK/ERK pathway plays a role in normal 
organogenesis; however, when aberrantly activated it 
can lead to malignant cellular proliferation, inhibition of 
apoptosis, and invasion.16 This mitogen-activated protein 
kinase (MAPK) pathway relays extracellular signals from the 
plasma membrane of the cell to the nucleus via an ordered 
series of phosphorylation events.17 Various extracellular 
stimuli, including growth factor-mediated activation of 
receptor tyrosine kinases (RTKs), lead to the sequential 
recruitment, phosphorylation, and activation of one of 
three RAS isoforms (designated KRAS, NRAS, HRAS), 
three RAF family members (ARAF, BRAF, CRAF) via a 
SRC-family tyrosine kinase,18–20 MEK (mitogen-activated 
ERK kinase),21–23 and ERK (extracellular signal-regulated 
kinase).21–23 Activated ERK translocates to the nucleus and 
phosphorylates several nuclear transcription factors necessary 
for cellular proliferation, differentiation, and survival.
Constitutive activation of the MAPK pathway occurs in 
90% of melanomas.24 The two most common mechanisms 
for MAPK pathway activation in melanoma are mutations 
in the BRAF (40%–60%) and NRAS genes (15%–30%).25,26 
The BRAF V600E mutation accounts for approximately 90% 
Table 1 Clinical trials of selected immune modulators in melanoma
Agent Phase Melanoma patients 
(n)
Observations Reference
Monoclonal antibodies
Anti-CTLA-4 
tremelimumab
3 655 Median OS 11.8 months (95% CI 10.4, 13.9)  
in the tremelimumab arm, and 10.7 months  
(95% CI 9.3, 12.0) in the chemotherapy arm,  
HR 1.04 (95% CI 0.84, 1.28)
126
Anti-PD-1 MDX-1106 1 10 1 PR, 2 MR 127
Anti-CD137 
BMS-663513
2 47 3 PR 128
Tumor vaccines
Recombinant MAGE-A3  
fusion protein
2 75 3 responses 129
gp100:209–217(210M)  
peptide
3 185 randomized to IL-2  
versus IL-2 + GP100
Overall RR 22.1% vs 9.7% 
(P = 0.0223) 
PFS 2.9 months (1.7–4.5) vs 1.6 (1.5–1.8)  
(P = 0.0101)
130
OncovEXGM-CSF* 2 43 6 CR, 6 PR, 7 SD of injected tumors 131,132
Note: *An oncolytic herpes simplex virus vector encoding granulocyte monocyte colony-stimulating factor (GM-CSF).
Abbreviations: CTLA4, cytotoxic T-lymphocyte-associated antigen 4; PD-1, programmed death-1; IL-2, interleukin 2; OS, overall survival; PFS, progression free survival; 
RR, response rate; HR, hazard ratio; PR, partial response; MR, minor response; CR, complete response; SD, stable disease.
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of all activating BRAF mutations.25 This protein product of 
the V600E mutation has demonstrated a 10.7-fold increase 
in kinase activity as compared with the wild-type protein.25 
Constitutive activation of BRAF and the MAPK pathway 
impart a proliferative and survival advantage to the cancer 
cell.27 Mutations in ARAF and CRAF have not been found in 
melanoma.28,29 Vemurafenib is a potent inhibitor of the acti-
vated V600E BRAF mutant protein and wild-type BRAF, but 
is a weak inhibitor of the A and CRAF isoforms.30
The second most common means for MAPK pathway 
activation in melanoma is through mutations in the NRAS 
gene.26 Somatic RAS mutations usually occur in codons 12, 
13, or 61 and maintain RAS protein in a constitutively active 
state.31 Mutations in the HRAS and KRAS isoforms are rare 
in melanoma.32–34 Interestingly, BRAF and RAS activating 
mutations are often mutually exclusive events, suggesting 
only one mutation within the same pathway is sufficient for 
pathway activation and denoting the redundant mechanisms 
of activating this pathway in melanoma pathogenesis. Of note, 
oncogenic RAS can also bind and activate PI3K, resulting 
in increased AKT activity.35 Thus, RAS activation leads to 
the upregulation of two major signaling cascades involved 
in melanoma: the MAPK and PI3K/AKT/mammalian target 
of rapamycin (mTOR) pathways. The mechanism of pathway 
activation and molecular response to specific targeted inhibi-
tion are likely to be determinants of sensitivity and clinical 
benefit to individual agents and combinations.
PI3K/AKT/mTOR pathway
The PI3K/AKT/mTOR pathway is another signaling 
transduction pathway that is aberrantly activated in several 
cancers, including melanoma.35 In response to activated 
RTKs, the PI3K phosphorylates phosphatidylinositol-4,5-
biphosphate to phosphatidylinositol-3,4,5-triphosphate 
(PIP3), recruiting other proteins to the plasma membrane and 
leading to activation of the major downstream effector of the 
PI3K pathway, AKT.36 Once active, AKT phosphorylates a 
number of substrates that promote cell survival, proliferation, 
and invasion.36 One substrate is the mTOR, a serine threonine 
kinase that modulates protein synthesis, angiogenesis, and 
cell cycle progression and validated therapeutic target in renal 
cell carcinoma, neuroendocrine tumors, and lymphoma.
Although activating mutations in PI3K are rare, down-
stream effectors PTEN and AKT, are altered in the major-
ity of melanomas.37,38 The tumor suppressor gene PTEN 
encodes a lipid and protein phosphatase that negatively 
regulates the PI3K cascade through dephosphorylation of 
PIP3.39,40 Decreased or loss of PTEN expression or function 
through epigenetic silencing, inactivating mutation or dele-
tion is observed in 30%–60% of primary melanomas.37,41–43 
  Interestingly, somatic mutations of PTEN gene occur in asso-
ciation with BRAF, but not NRAS mutations suggesting the 
dual pathway activation can be accomplished by alterations 
in NRAS alone or the combination of PTEN and BRAF.25,44 
In contrast, AKT is an oncogene that encodes a kinase that 
is frequently activated in human cancers.45 There are three 
AKT isoforms and AKT3 is the major isoform deregulated 
in melanoma.37 Overexpression of phospho-AKT, typically 
associated with increased gene copy number, is seen in a 
greater proportion of melanomas and melanoma metastases 
than nevi37,45 and may be associated with earlier progression 
and shorter survival of patients with melanoma.46 Inhibition 
of AKT3 using small interfering RNA or increased activa-
tion of PTEN stimulated apoptosis of melanoma cell lines, 
indicating a prosurvival function of AKT in melanoma.37 
In vitro cell line and in vivo mouse xenograft studies of 
simultaneously targeting AKT3 and V600E BRAF with 
small interfering RNAs led to increasing cellular apoptosis 
and decreasing proliferation supporting the relevance of both 
pathways in melanoma.47
Cell growth, proliferation, and survival
Invasion and metastasis
Tumor-induced neo-angiogenesis
Nucleus
Cytoplasm
RAS
PTEN
Cell membrane
RTKs recruit RAS to the cell
membrane leading to activation
of signaling cascades
Binding of specific growth
factors (eg,.: c-KIT, FLT-3,
PDGF, VEGF) activate
membrane RTKs
P
RAF
MEK
ERK
P13K
AKT
mTOR
Figure 1 Molecular pathogenesis of melanoma.
Abbreviations: AKT, Protein Kinase B; ERK, extracellular signal-regulated kinase; 
FLT-3, FMS-like tyrosine kinase 3; MEK, mitogen-activated ERK extracellular signal-
regulated kinase; mTOR, mammalian target of rapamycin; PDGF, platelet-derived 
growth  factor;  PI3K,  phophoinositol-3-kinase;  PTEN,  phosphatase  and  tensin 
homolog; RAF, murine sarcoma viral oncogene; RAS, rat sarcoma oncogene; RTK, 
receptor tyrosine kinase; vEGF, vascular endothelial growth factor.
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c-KIT
c-KIT (also known as CD117) is a RTK that also contributes 
to the pathogenesis of a subset of melanomas that do not 
harbor NRAS or BRAF mutations. c-KIT activates several 
signaling cascades, including the MAPK, PI3K/AKT/
mTOR, and microphthalmia associated transcription factor 
pathways.48,49 c-KIT signaling is necessary for differentiation, 
proliferation, and migration of normal melanocytes. c-KIT 
mutations and/or copy number increases were identified in 
the melanomas from mucosa, acral and chronic sun-induced 
damaged skin.50 Point mutations in this gene result in con-
stitutive activation of downstream effectors of key signaling 
pathways in melanoma cells.51,52 Although the frequency of 
c-KIT alterations is reported to be lower in Chinese, Korean, 
and Australian cohorts53–55 compared to Western patients, 
such aberrations have been identified in Chinese patients with 
nonchronic sun-damaged skin and melanomas of unknown 
primary.54 Geographical variability in predisposing risk fac-
tors, small study sample sizes, incomplete testing of the c-KIT 
gene, and differing criteria for solar elastosis, the marker of 
chronic sun-damage may explain the apparent variation on 
KIT mutation frequencies between populations.
The above laboratory and clinical studies support the 
importance of activating c-KIT and components of the PI3K 
and MAPK pathways for melanoma pathogenesis. Based on 
this evidence, activation may occur through NRAS muta-
tions that activate both the PI3K and MAPK pathways, or 
concurrent BRAF mutations with altered function of either 
PTEN or AKT, or through c-KIT mutations. Although these 
are not the sole alterations that contribute to melanoma 
pathogenesis, the clinical and laboratory results provide the 
initial rationale for testing specific agents and combinations 
in melanoma patients.
Potential targeted treatments for 
patients with advanced melanoma 
Agents targeting the MAPK pathway
Agents targeting the MAPK pathway are the first small 
molecule kinase inhibitors to demonstrate clinical benefit 
for melanoma patients. Agents that have entered into clinical 
testing can be grouped into those that are relatively specific 
for BRAF and/or mutant BRAF, nonspecific RAF inhibitors, 
and MEK inhibitors. Clinical trials of agents within these 
classes show varying activity and toxicity that may be due 
to the pharmacology of the individual agents (ie, specificity 
and potency of target inhibition) and to the specific tumor 
molecular profile of patients. Pharmacodynamic studies 
suggest that .80% inhibition of ERK is needed for clinical 
activity.56 Common adverse events are rash, fatigue, nausea, 
and diarrhea. Specific toxicities include the development 
of cutaneous keratoacanthoma or squamous-cell carci-
noma with specific BRAF inhibitors, and retinal toxicity 
(central serous retinopathy and retinal vein occlusion) with 
MEK inhibitors.
Laboratory results suggest there are feedback loops within 
the MAPK system of biological and clinical relevance and 
that genotype may determine the activity of specific agents. 
For instance, the development of borderline and malignant 
skin tumors such as keratoacanthomas and squamous-cell 
carcinomas associated with BRAF inhibitors, is thought 
to arise due to paradoxical MAPK signaling in cells with 
wild-type BRAF.57 Clinical studies show that inhibition of 
wild-type RAF leads to upregulation of RAS signaling and 
ERK activation. Moreover, the results of three studies suggest 
that inhibitors thought to be selective for mutant BRAF can 
also activate CRAF through the formation of dimeric RAF 
complexes – a process that is enhanced by the presence of 
an oncogenic RAS mutation.58–61 These studies support the 
conclusion that mutant-specific BRAF inhibitors should be 
used for treating cancers caused by BRAF mutants (such 
as BRAF V600E-associated melanomas), but should not be 
used as single agents in melanomas (and other cancers) with 
RAS mutations as they may promote tumor genesis. Such 
mechanistic insight into both normal and pathogenic MAPK 
signaling suggest that certain agents and combinations may 
be preferable in certain molecular contexts and lead to the 
development of effective new anticancer therapies.
Selective mutant BRAF-inhibitor 
vemurafenib
Vemurafenib (PLX-4032, RG7204) is an inhibitor of a 
mutant form of the BRAF kinase and the second agent, 
after ipilimumab, to improve OS in patients with advanced 
melanoma.15 In the Phase III study, named BRIM 3 (BRAF 
Inhibitor in Melanoma 3), previously untreated patients with 
advanced melanoma that harbored the V600E mutation, 
were randomized to either vemurafenib or dacarbazine. 
A significant improvement in 6-month OS was observed in 
the vemurafenib group versus the dacarbazine group (84% 
versus 64%, respectively). In the interim analysis for OS 
and final analysis for progression-free survival (PFS), vemu-
rafenib was associated with a significant relative reduction 
of 63% in the risk of death and of 74% in the risk of either 
death or disease progression compared with dacarbazine. 
Common adverse events associated with vemurafenib were 
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arthralgia, rash, fatigue, alopecia, photosensitivity, nausea, 
and diarrhea. Cutaneous squamous-cell carcinoma, keratoa-
canthoma, or both developed in 18% of patients. All lesions 
were treated by simple excision. This trial was the first to 
show that a rationally targeted agent improved survival 
by inhibiting an aberrantly overactive signaling pathway 
in melanoma.
Resistance to vemurafenib
Despite the benefits observed with vemurafenib, both intrin-
sic and acquired resistance has been observed in patients 
with advanced melanoma. Emerging evidence suggests that 
resistance to vemurafenib is complex and multifactorial. 
Preclinical studies suggest that PTEN loss, C-RAF muta-
tions, or Cot-1 mutations may confer intrinsic resistance 
to vemurafenib.62,63 Vemurafenib-mediated apoptosis was 
  significantly impaired in PTEN negative melanoma cell 
lines.63 Moreover, screening for kinases that prevented 
vemurafenib-mediated cell growth arrest identified both 
CRAF and Cot1 as potential drivers of resistance.62 Both 
CRAF and Cot 1 bypass BRAF signaling, activating the 
MAPK pathway. Although these studies may make mecha-
nistic sense, no study has demonstrated that pre-existing 
alterations in PTEN, CRAF, or Cot-1 predict for intrinsic 
resistance to vemurafenib.
In attempts to identify the genetic changes that lead to 
acquired resistance to vemurafenib, researchers have com-
pared matched tumor samples from patients prior to treatment 
and after treatment failure. Cot-1 mRNA levels, and insulin-
like growth factor recptor-1 and platelet-derived growth fac-
tor receptor (PDGFR) immunohistochemistry staining have 
all been found to be elevated in post-treatment samples when 
compared to pretreatment biopsies.62,64,65 Moreover, RAS or 
MEK activating mutations, that were not present in the pre-
treatment tumor, have been identified in tumors from patients 
progressing on vemurafenib treatment.64,66 A common theme 
in these mechanisms of resistance is the restoration of MAPK 
signaling and/or an increase in PI3K/AKT/mTOR signaling, 
emphasizing the importance of these pathways on melanoma 
progression. By understanding the molecular events that lead 
to resistance, rational combinations or subsequent treatments 
can be designed.
Other selective BRAF inhibitors
Selective inhibitors of BRAF are in development including 
SB90885, GDC-0879, and GSK2118436 (GSK436). The 
most detailed clinical information is available for the latter 
and is summarized in the next column.
GSK436
GSK436 is a highly potent and selective adenosine-5′-
triphosphate (ATP)-competitive BRAF inhibitor. The selec-
tivity of this agent for mutant BRAF is over 100 times greater 
than the wild-type protein.67 It displays dose-dependent inhi-
bition of MEK and ERK phosphorylation in mutant BRAF 
cell lines and tumor regression in xenograft models.67 In the 
first-in-human Phase I study, 61 patients (57 with BRAF 
mutations) had been accrued and the maximum tolerated 
dose had not yet been determined by the time the study 
was reported (see Table 2).68 In patients with mutant BRAF 
melanoma, a response rate of 63% (10 of 16 patients) was 
observed in the patients receiving doses $150 mg twice a 
day. Cohorts receiving lower doses had a response rate of 39% 
(26 of 41 patients, one CR, and 25 partial responses [PRs]). 
The probability of response to GSK436 directly correlated 
with the presence of a BRAF mutation and inversely with the 
presence of a PTEN alteration. Due to its high response rate 
and reasonable toxicity profile, GSK436 is being evaluated 
in combination with the MEK inhibitor GSK1120212 in an 
attempt to enhance the clinical activity (discussed further 
below).
Nonselective BRAF inhibitors
Sorafenib
Sorafenib is a small molecule inhibitor of multiple kinases, 
including wild-type BRAF, V600E BRAF, and CRAF as well 
as vascular endothelial growth factor receptors (VEGFR) and 
PDGFR.69,70 Inhibition of the MAPK pathway has been dem-
onstrated in vitro and in vivo with this agent. Sorafenib has 
limited single agent activity in patients with melanoma.71,72 
Although interesting clinical activity was reported from a 
Phase II trial of sorafenib combined with carboplatin and 
paclitaxel,73 the Phase III trials testing this combination in 
the first- and second-line settings did not show improve-
ments in response rate, PFS, or OS (Table 2).74,75 Currently, 
clinical investigations are focused on combining sorafenib 
with other targeted, immunomodulatory, and chemotherapy 
agents (see Table 3).
RAF265
RAF265 is also a multitargeted small molecule inhibitor of 
both the V600E BRAF mutant and VEGFR. A Phase I trial 
treating advanced melanoma patients with RAF265 dem-
onstrated an overall response rate of 16% (6 of 37 patients) 
for BRAF mutation-positive melanoma patients and 13% 
(4 of 30) for wild-type or BRAF mutation status unknown 
patients (see Table 2).76 Because of dose limiting hematologic 
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  toxicity, an intermittent schedule will be explored in an effort 
to improve the therapeutic index. Whether this agent offers 
particular advantage over more selective and effective BRAF 
inhibitors, such as vemurafenib and GSK2118436, will be 
determined in future clinical trials.
MEK inhibitors
MEK is an attractive therapeutic target as it is downstream 
of both activated BRAF and NRAS. Preclinical studies 
suggested that melanoma cell lines with mutant BRAF 
were more sensitive to MEK inhibition than those har-
boring activating NRAS mutations and wild-type BRAF 
genes.77 Small-molecule inhibitors of MEK completely 
abrogated tumor growth in BRAF mutant xenografts, 
whereas RAS mutant tumors were only partially inhibited.77 
Agents that entered clinical development include CI-1040, 
PD-0325901, GSK1120212, and AZD6244. The activity of 
first- and second-generation MEK inhibitors CI-1040 and 
PD-0325901 has been limited by pharmacologic and   toxicity 
issues. Cl-1040 was an agent that was generally tolerated 
well, but it failed to demonstrate sufficient anticancer activity 
to warrant further   development.78 PD-0325901 is structurally 
similar to Cl-1040, but is more potent at MEK inhibition and 
has greater systemic exposure. In Phase I trials, melanoma 
patients achieved objective responses, and suppression of 
phosphorylated ERK in melanoma specimens.78,79 However, 
clinical development was terminated because of unex-
pected high incidence of musculoskeletal and neurological 
adverse events (see Table 2). Newer MEK inhibitors such 
as GSK1120212 appear to have greater potency and have 
demonstrated promising clinical activity, particularly in 
tumors with BRAF mutations.
GSK1120212
GSK1120212 (GSK212) is a reversible, selective allosteric 
inhibitor of both MEK1 and MEK2. Preclinical studies have 
demonstrated that it can inhibit the phosphorylation of ERK 
and had growth inhibition in a variety of cancer cell lines.80 
The first-in-human Phase I study of GSK212 determined the 
recommended Phase II dose to be 2 mg daily (see Table 2).81 
Table 2 Clinical trials of single-agent kinase inhibitors in melanoma
Agent Phase Number of melanoma patients  
evaluable for response (n)
Response observed  
in melanoma patient(s)
Reference
c-KIT inhibitors
Imatinib 2 16 No objective responses 103
Imatinib 2 21 1 PR, 4 SD 102
Imatinib 2 25 No objective responses, 2 SD 104
Imatinib 2 43 c-KIT positive 10 PR, 13 SD 
mPFS = 3.5 months, 6 months,  
PFS rate = 36.6%
101
Imatinib 2 25 2 CR, 4 PR 100
Dasatinib 2 36 2 PR 105
Multi-target BRAF inhibitors
Sorafenib 2 30 0 CR, 0 PR, 7 SD, 23 PD 72
RAF265 (CHIR-265) 1 76 The overall response rate by  
RECIST 1.0 was 6/37 (16%) for  
mut BRAF pts and 4/30 (13%)  
for wt (3)/unknown (1) BRAF pts
76
Selective BRAF inhibitors
GSK2118436 1/2 57 BRAF mutation positive 1 CR, 25 PR 68
MEK inhibitors
PD-0325901 1 48 0 CR, 3 PR, 10 SD 78
PD-0325901 1 7 1 CR 79
GSK1120212 1 42 BRAF mutation positive: 2 CR, 6 PR 
BRAF wt: 2 PR
81
AZD6244 R2 104 6 PR 83
AKT inhibitors
Perifosine 2 14 0 CR, 0 PR 86
mTOR inhibitors
Temsirolimus 2 33 1 PR 91
Everolimus 2 53 2 PR 92
Abbreviations: OS, overall survival; PFS, progression free survival; HR, hazard ratio; RR, response rate; PR, partial response; MR, minor response; CR, complete response; 
SD, stable disease; mut, mutant; wt, wild-type; pts, patients.
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Common toxicities were grade 1 and 2 rash and   diarrhea. 
There were three cases of reversible central serous retinopathy. 
Seventy-two of 162 patients enrolled in the study had 
advanced melanoma. Of the patients with melanoma, 24 
tumors harbored BRAF mutations, 24 had a wild-type BRAF 
gene, and 22 had an unknown BRAF status. There were two 
CRs and six PRs among 20 evaluable patients with BRAF 
mutant melanoma for a preliminary objective response rate 
of 40%. In contrast, two of 22 evaluable patients with BRAF 
wild-type melanomas had PRs. These results suggest that 
response correlates with BRAF mutation status. Activity in 
some BRAF wild-type melanoma tumors suggest that these 
are also dependent on the MAPK pathway by mechanisms 
unrelated to most common BRAF mutations. Trials of drug 
combinations are currently being tested to improve the effi-
cacy of this agent.
AZD6244
AZD6244 (formerly called ARRY-142886) is a selective 
non-ATP competitive inhibitor of MEK1 and MEK2.82 In a 
Phase II trial, 210 patients with advanced melanoma were 
randomly allocated to AZD6244 or temozolomide (see 
Table 2).83 Although there was no significant difference in 
the primary endpoint of PFS between the two arms, five of 
six patients with PRs from AZD6244 had BRAF V600E-
mutated tumors. The activity observed warrants further 
investigation of this agent in combination with other drugs 
in selected patients.
Table 3 Clinical trials of combinations in melanoma
Agent Combination Phase Melanoma patients  
evaluable for  
response (n)
Response or endpoints  
observed in melanoma  
patient(s)
Reference
Multi-target BRAF inhibitors
Sorafenib Interferon alpha 1 1 with the remaining  
12 being renal cell cancer
1 SD 133
Sorafenib Pegylated  
Interferon alpha
2 41 3 PR, 14 SD 134
Sorafenib Dacarbazine R2 51 in the sorafenib  
and dacarbazine arm
CR + PR = 12 
There were statistically significant  
improvements in PFS rates at 6 and  
9 months, and in TTP in favor of the  
sorafenib plus dacarbazine arm.  
No difference in OS was observed
135
Sorafenib Dacarbazine 2 74 0 CR, 8 PR, 34 SD, 32 PD 136
Sorafenib Carboplatin  
and Paclitaxel
1/2 34 11PR, 19 SD 73
Sorafenib in the first-line setting Carboplatin  
and Paclitaxel
3 409 pts on the sorafenib, 
carboplatin,  
and paclitaxel arm
No difference in OS, PFS, or RR 74
Sorafenib in the second-line  
setting
Carboplatin  
and Paclitaxel
3 135 pts in both arm No difference in OS, PFS,  
or incidence of best response
75
Sorafenib Temsirolimus 1 23 0 CR, 0 PR, 10 SD 112
Sorafenib Tipifarnib 1 7 0 CR, 0 PR, 3 SD 118
Sorafenib Temsirolimus  
or Tipifarnib
R2 Arm A – Sorafenib  
and temsirolimus arm:66 
Arm B – Sorafenib  
and tipifarnib
Arm A: 0 CR, 3 PR, 24 SD 
Arm B: 0 CR, 1 PR, 10 SD
119
Selective BRAF inhibitors
GSK2118436 GSK1120212 1/2 No prior BRAF inhibitor: 71 
Prior BRAF inhibitor: 24
without prior BRAF inhibitor:  
5 CR, 44 PR, 22 SD. 
Prior BRAF inhibitor: 0 CR, 3 PR
125
VEGF inhibitor
Bevacizumab Everolimus 2 57 1 CR, 6 PR, 33 SD  
The median PFS and OS were  
4 months and 8.6 months  
respectively
122
Bevacizumab Ipilimumab 1 22 1 CR, 6 PR, 7 SD 123
Abbreviations: OS, overall survival; PFS, progression free survival; HR, hazard ratio; RR, response rate; PR, partial response; MR, minor response; CR, complete response; 
SD, stable disease; mut, mutant; pts, patients.
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The activity of MEK inhibitors in some patients 
with BRAF wild-type melanomas seen with GSK212 
and AZD6244 suggest that there are other mechanisms 
determining sensitivity to MEK inhibition. Results from 
laboratory studies evaluating inhibitors across multiple cell 
line panels indicate that MEK inhibitor activity does not 
absolutely correlate with the mutational or phosphorylation 
status of BRAF, MEK, RAS, or PI3K.84 This lack of correla-
tion has fueled efforts to develop expression profiles of MEK 
activation and sensitivity. An 18-gene expression signature of 
MEK activation and inhibition derived from multiple tumor 
cell lines and xenografts may correlate with sensitivity and 
be used as a marker of pharmacodynamics response to MEK 
inhibition.85 A 13-gene signature was also identified that was 
predictive of resistance to a MEK inhibitor in cancer cells, 
despite these cells having functional MEK activity. These 
signatures potentially may be used to select patients sensitive 
and resistant to MEK inhibition.84
Agents targeting  
the PI3K/AKT/mTOR pathway
In contrast to the clinical benefits seen with agents targeting 
the MAPK pathway tested in melanoma patients, the results 
from clinical trials evaluating agents targeting the PI3K/AKT/
mTOR pathway have been disappointing. There are a number 
of potential explanations for the lack of activity: (1) subop-
timal pharmacology and target modulation of the agents at 
maximum tolerable doses, (2) relative lack of importance 
of the pathway as a driver of melanoma cell proliferation or 
survival, (3) intrinsic or rapid onset of acquired resistance 
to target inhibition, or (4) failure to enrich enrollment into 
trials for patients likely to benefit. Unfortunately, not all trials 
have incorporated pharmacodynamics assessment of target 
inhibition in tumor or surrogate tissue nor employed patient 
enrichment strategies, thus further evaluation of emerging 
agents targeting the pathway with better pharmacology is 
warranted. Descriptions of agents and results from clinical 
trials are provided in the following sections.
AKT inhibitors
PI3K/AKT/mTOR pathway is another signaling transduc-
tion pathway that is aberrantly activated in melanoma and 
pharmacological inhibition may also benefit patients with 
melanoma.35 Although a number of PI3K inhibitors are in 
clinical development and may have activity in PTEN mutant 
tumors, inhibiting downstream targets AKT or mTOR may 
be preferable due to the frequency of AKT amplification 
in melanomas. Despite this finding, the activity of AKT 
inhibitors perifosine and GSK2141795 as single agents in 
the treatment of advanced melanoma has been disappointing. 
These initial results may be due to issues of pharmacology 
of the individual agents and lack of optimal target inhibition 
in tumor due to off-target or target-specific toxicity-limiting 
doses.
Perifosine
Perifosine is an AKT and PI3K inhibitor and structurally 
related to miltefosine. It interferes with the recruitment of 
proteins with the pleckstrin homology domain, like AKT, 
to the plasma membrane. A Phase II study of perifosine 
treatment in previously untreated patients with metastatic 
melanoma was conducted and of 14 evaluable patients, none 
achieved an objective response (see Table 2).86 The extent 
of AKT or MAPK pathway inhibition was not evaluated in 
this study. The authors recommended that no further devel-
opment of single agent perifosine was required in metastatic 
melanoma patients.
GSK2141795
GSK2141795 (GSK795) is a reversible, selective ATP-
competitive inhibitor of all AKT isoforms. Preclinical studies 
had demonstrated that GSK795 could inhibit proliferation 
of cancer cell lines. A Phase I trial has been conducted with 
GSK795 to determine the recommended Phase II dose, 
pharmacokinetics, pharmacodynamics, and safety of the 
drug.87 In total, 76 patients were enrolled. In the 54 patients 
evaluable for response, one PR was observed in a patient 
with metastatic anal cancer, two patients with endometrial 
cancer had prolonged stable disease (SD) and minor tumor 
responses in a population selected for molecularly defined 
predictive signatures (PTEN loss or PIK3CA mutations). 
No responses were observed in the patients with melanoma, 
although few were enrolled in this study.
mTOR inhibitors
Inactivating PTEN mutations are identified in 50% of 
melanomas.88 The resulting increase in activity of mTOR is 
believed to derail the normal control of nutrients leading to 
excessive cell growth and proliferation.89 However, the results 
from early Phase clinical trials testing mTOR inhibitors and 
rapamycin derivatives, temsirolimus and everolimus, in mela-
noma patients have also shown limited single agent activity.
Temsirolimus
Temsirolimus is an intravenous mTOR kinase inhibitor 
and ester derivative of rapamycin. When bound to FK506 
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binding protein, it interacts and inhibits the mTOR kinase 
activity, resulting in inhibition of the cell cycle.90 Preclinical 
studies of temsirolimus demonstrated that it could inhibit 
tumor activity in a variety of cancers including melanoma 
cell lines and animal models. A Phase II trial of temsiroli-
mus was conducted in patients with metastatic melanoma 
(see Table 2).91 Thirty-three patients were treated with only 
one patient experiencing a PR lasting 2 months. The median 
time to disease progression was 10 weeks. Of note, the dose/
schedule used in this trial is not the maximum tolerated dose 
and target inhibition in tumor was not evaluated in this trial. 
Whether antitumor activity would be greater with higher 
doses is an unanswered question.
Everolimus
Everolimus is an oral mTOR inhibitor. A two-stage Phase 
II trial was conducted in 29 patients with metastatic mela-
noma (see Table 2).92 By the first interim analysis, the activ-
ity of everolimus looked favorable with 35% of patients 
experiencing SD at 16 weeks. The median PFS and OS were 
just over 3 months and 12 months, respectively. To further 
investigate the activity of everolimus, the enrollment of a 
second cohort treated with a higher dose was conducted. 
An interim analysis of the second cohort found the median 
PFS and OS was just under 2 months and 9.5 months 
respectively, tempering the enthusiasm generated by the 
activity observed in the first cohort. Of the 53 patients 
enrolled in total, two patients had unconfirmed PRs. The 
authors concluded that everolimus as a single agent had 
insufficient activity in metastatic melanoma patients. The 
reason as to why patients treated at the lower dose had 
longer survival compared with those treated at higher 
doses is unknown.
c-KIT inhibitors
Three commercially available, orally administered small 
molecule tyrosine kinases inhibitors, imatinib, dasatinib, and 
nilotinib, are under evaluation in melanoma. While all three 
agents inhibit c-KIT, PDGFR, and BCR-ABL, they differ in 
potency of inhibition, cellular uptake, mechanism interaction 
with kinase, and overall inhibitory profile for other cellular 
kinases.67,93,94 The three agents were initially approved for the 
treatment of patients with chronic myelogenous leukemia 
which results from the translocation product BCR-ABL.95–97 
Both imatinib and dasatinib have demonstrated activity in 
gastrointestinal stromal tumors, which harbors activating 
mutations in c-KIT or PDGFR.98,99 Results suggest that these 
agents may have activity in c-KIT mutated and, possibly, 
c-KIT amplified melanomas.
Imatinib mesylate
Five Phase II trials of single agent imatinib have been con-
ducted (see Table 2) and the results of these trials demonstrate 
the importance of patient selection based on the presence of 
mutations in tumors.100–104 Across three trials conducted in 
patients with mostly nonchronically sun-damaged melanomas 
and not requiring c-KIT mutation for enrollment, only one 
of 65 patients achieved a PR, and that patient had a c-KIT 
mutation-positive acral melanoma.102–104 In contrast, two 
published Phase II studies that required patients to harbor 
melanomas with c-KIT mutations reported dramatically dif-
ferent results.100,101 Across these two studies, there were two 
CRs and 14 PRs among 65 evaluable patients, for a response 
rate of almost 25%. Responses were seen in melanomas with 
c-KIT mutations with known functional relevance. Mutations 
in c-KIT exons 11 and 13 seemed to correlate better with 
response than either amplifications or c-KIT overexpression 
assessed by immunohistochemistry.67 These promising results 
with imatinib in this molecular subgroup of melanoma patients 
warrant confirmation in a prospective randomized trial.
Dasatinib
A Phase II study in a molecularly unselected population of 
advanced melanoma patients has recently been published (see 
Table 2).105 Of the 36 patients evaluable for response, two had a 
PR lasting 24 weeks or more. One of these patients was found 
to have a c-KIT mutation. The other responder had a wild-type 
c-KIT gene, but amplification of c-KIT was not tested in this 
study. The activity of the drug in patients with melanomas likely 
to carry c-KIT aberrations is currently being evaluated.106
Nilotinib
Nilotinib is a second-generation tyrosine kinase inhibitor 
of c-KIT, PDGFR, and BCR-ABL. Nilotinib has similar 
potencies against c-KIT and PDGFR compared to ima-
tinib.67   However, the agents differ with respect to cellular 
transport, where imatinib is transported actively and nilo-
tinib is transported passively. Due to this passive diffusion, 
nilotinib may achieve higher intracellular concentrations and 
be subject to less extrinsic resistance mechanism as com-
pared with imatinib.67 Several Phase II studies are currently 
recruiting patients with melanomas from acral, mucosal, 
and chronically sun-damaged skin or melanomas that harbor 
c-KIT aberrations.107–111
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New treatment paradigm  
for advanced melanoma
Ipilimumab and vemurafenib are poised to become the ther-
apy of choice for patients with previously untreated advanced 
melanoma. The initial treatment for patients with tumors 
that harbor the BRAF V600E mutation will be vemurafenib, 
while those patients harboring wild-type BRAF tumors will 
be treated with ipilimumab. However, despite the advances 
observed with these agents, both intrinsic and acquired 
resistance has been observed and no standard second-line 
treatment has been established. Hence, further research into 
the molecular predictors and mechanisms contributing to 
resistance will aid in the design of rational treatment com-
binations and regimens to employ after treatment failure. 
Research into the molecular pathogenesis of melanoma and 
its dependence on particular signaling cascades will aid in 
these efforts.
Combinations of targeted agents  
in melanoma
Intrinsic and acquired resistance to novel targeted agents 
is likely due, in part, to the cross talk that occurs between 
the pathways required for melanoma development and 
progression. Coordinated blockade of multiple pathways 
with combinations of targeted agents will hopefully lead to 
improved treatment efficacy. With the goal of overcoming 
resistance and enhancing clinical efficacy, a Phase I/II trial 
is opening soon evaluating the combination of ipilimumab 
and vemurafenib in subjects with metastatic melanoma 
and the mutant form of BRAF (clinicaltrials.gov identifier: 
NCT1400451). Other combinations of targeted agents are 
currently in varying phases of development. Combination 
strategies have focused on: (1) inhibiting additional targets 
within the same pathway or (2) inhibiting a different pathway 
or cellular process that are involved in the pathogenesis or 
drug resistance of melanoma. Trials combining CTLA4 and 
other immunomodulatory antibodies, and/or vaccines are also 
underway. In general, vaccine development strategies may 
benefit most from combinations with novel immunomodulat-
ing monoclonal antibodies. These strategies are based on our 
current understanding of melanoma targets/pathways, avail-
ability of the agents, and limited preclinical experiments that 
suggest at least additive efficacy of the combination. Results 
to date suggest that activity of a combination is related to 
obtaining effective inhibition of the individual targets without 
inducing significant additional normal tissue toxicity.
Inhibiting targets in parallel 
pathways
Sorafenib and temsirolimus
As single agents, sorafenib and temsirolimus have modest 
antimelanoma activity; however, these agents inhibit targets 
within the parallel signaling pathways and have limited 
overlapping toxicities. Hence the combination of sorafenib 
and temsirolimus was expected to produce at least additive 
activity and have a tolerable side effect profile. The results of a 
Phase I study of a combination of sorafenib and temsirolimus 
in patients with advanced melanoma did not meet these 
expectations (see Table 3).112 Dose escalations of the individual 
agents were impeded by higher than expected rates of toxicity. 
There were no responses among 23 evaluable patients, although 
ten patients had SD of 8–24 weeks. The combination did have 
effects on target modulation, as both phosphorylated MEK and 
AKT decreased from pre- and on-treatment tumor biopsies. 
However, there was no trend in the change of phosphorylated 
ERK with the combination   treatment. The reason for the 
decrease in phosphorylated MEK and not ERK is unknown, 
but probably speaks to the complexity of crosstalk amongst 
these pathways and challenges of assessing pharmacodynamics 
markers in clinical trials.
Sorafenib and tipifarnib
The frequency of activating RAS mutations in melanoma 
and most cancers suggest that it would be an ideal target for 
inhibition. Unfortunately, no direct inhibitor of RAS has been 
developed, as it lacks an accessible small molecule binding 
site. One strategy indirectly inactivates RAS function by 
inhibiting the post-translational modifications required for the 
full biological activity of RAS. RAS undergoes farnesylation 
to associate with the plasma membrane and is subsequently 
activated.113 Inhibitors targeting farnesyl transferase, the 
enzyme that catalyzes this modification, have been developed 
and tested in patients with advanced melanoma. The major-
ity of farnesyl transferase inhibitors have limited activity 
as single agents and in combination with chemotherapy in 
melanoma patients.114–117 However, several trials combining 
farnesyl transferase inhibitors with other targeted agents in 
patients with melanoma are underway. A Phase I trial evalu-
ating the combination of the farnesyl transferase inhibitor, 
tipifarnib with sorafenib in patients with advanced malignan-
cies has been reported (see Table 3).118 Evidence of target 
modulation was seen in a quarter of patients with a 50% or 
more reduction in farnesyl transferase levels. Three of seven 
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melanoma patients had SD. One patient with prolonged SD 
had a PDGFR mutation. It is unknown whether the observed 
response was due to sorafenib, which is known to inhibit 
PDGFR, or the combination of both agents.
Another randomized Phase II trial in molecularly unse-
lected metastatic melanoma patients tested the combina-
tions of sorafenib and temsirolimus (Arm A) or sorafenib 
and tipifarnib (Arm B) (see Table 3).119 Significant toxicity 
limiting dose escalation was seen with both combinations. 
Among 66 evaluable patients in Arm A, there were three 
PRs (5%) and 24 SD (36%). Of the 42 evaluable patients in 
Arm B, there was one PR (2%) and ten SDs (24%). Based on 
these results, neither combination appear to show sufficient 
activity for further evaluation, possibly due to poor pathway 
inhibition at tolerated doses.
Bevacizumab and everolimus
Vascular endothelial growth factor (VEGF) is frequently 
overexpressed in melanoma and high levels of VEGF may 
represent an adverse prognostic feature.120 Aberrant activity 
of the VEGF pathway results in tumor angiogenesis and 
monocyte/macrophage migration. Concurrent inhibition 
of tumor and endothelial cell proliferation by combining a 
VEGF inhibitor with an mTOR inhibitor like everolimus, 
which also down regulates the VEGF receptor may be 
efficacious. The combination of the VEGF monoclonal anti-
body bevacizumab and everolimus has activity in metastatic 
clear cell renal carcinoma.121 A Phase II study involving 
57 patients with metastatic melanoma evaluated the efficacy 
and safety of bevacizumab and everolimus. Seven patients 
(12%) experienced objective responses (1CR, 6PR) and 
33 had SD (58%) (see Table 3).122 The median PFS and OS 
were 4 months and 8.6 months, respectively. This activity 
is greater than expected for the individual agents and the 
researchers recommended further exploration of these agents 
in other combinations.
Ipilimumab and bevacizumab
The activity of immunological therapies may in part be 
related to damage to the tumor vasculature. Ipilimumab 
induces a hemorrhagic necrosis of tumors that is likely 
due in part to immune mediated vasculopathy.123 Similar 
changes are observed in metastases of patients with durable 
clinical responses to CTLA-4 antibody blockade and vac-
cination with irradiated autologous tumor cells engineered 
to secrete GM-CSF.124 In these patients, high titer antibod-
ies are produced against VEGF, suggesting ipilimumab 
and other immunotherapy may induce host responses that 
target angiogenic networks in the tumor microenvironment. 
In addition, VEGF not only affects tumor angiogenesis, it 
also potently inhibits the maturation of antigen presenting 
cells and thus may contribute to the ability of tumors to evade 
the host immune response. Based on these observations, the 
combination of ipilimumab and bevacizumab was studied 
in a Phase I study (see Table 3).123 Among 22 patients evalu-
able for response, six (27%) PRs, one (5%) CR, and seven 
(32%) durable SDs were observed. Serial perfusion computed 
tomography scans showed a persistent decreased tumor blood 
flow, and post-treatment biopsies in twelve patients revealed 
activated vessel endothelium with extensive T-cell trafficking 
and nonproductive central angiogenesis. Clinical activity and 
correlative studies suggest additive to synergistic effects with 
the combination of ipilimumab and bevacizumab and that 
this combination merits further exploration.
Inhibiting targets within  
the same pathway
Combined BRAF and MEK inhibition
The most promising combination strategy under evaluation is 
the simultaneous inhibition of BRAF and MEK. Promising 
evidence derived from a BRAF V600E human melanoma 
xenograft model, illustrated that combined administration of 
BRAF inhibitor GSK2118436 (GSK436) and MEK inhibitor 
GSK1120212 (GSK212) lead to greater antitumor activity 
compared to either monotherapy and decreased incidence 
of the BRAF inhibitor induced hyper-proliferative skin 
lesions.125 In fact, a Phase I/II trial has been conducted with 
the combination of GSK436 and GSK212 in patients with 
tumors harboring V600 BRAF mutations, 93% (n = 101 
patients) with advanced melanoma (see Table 3).125 Full 
monotherapy doses were tolerated in combination and the 
common adverse events included: pyrexia, rash, chills, nau-
sea, vomiting, diarrhea, and fatigue. Grade 3 neutropenia 
and leukopenia were also observed in only three and two 
patients respectively. As predicted by the xenograft model the 
co-administration of a MEK inhibitor lowered the incidence 
of rash and hyper-proliferative skin lesions, presumably 
by GSK212 blocking the BRAF inhibitor-induced activa-
tion of the MAPK pathway in cells with a wild-type BRAF 
gene. Forty-one of 71 patients with advanced melanoma 
and no prior exposure to a BRAF inhibitor had objective 
responses. Of 24 patients that had previous BRAF inhibitor 
therapy, three had PRs. These results exemplify the fact that 
combination treatments targeting the same pathway may be 
tolerable, reduce mechanism-based toxicity, and potentially 
enhance activity.
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Conclusion
Improvements in the understanding of the molecular underpin-
nings of melanoma have finally translated into targeted therapies 
that improved survival for patients with advanced melanoma. 
Ipilimumab and vemurafenib are now the first-line treatment 
options for patients. CTLA4, other immune modulatory anti-
bodies, and vaccines may play a crucial role in initiating and 
maintaining a melanoma specific immune response. Vaccine 
development strategies may benefit most from combinations 
with novel immune modulating monoclonal antibodies. In 
early Phase clinical trials of small molecule kinase inhibitors, 
there has been some significant antitumor activity identified in 
unique molecular subsets of melanoma patients. Research is 
currently focused on understanding the mechanisms of intrinsic 
and acquired resistance to these agents. These advances will 
lead to rationally designed combinations of first- and second-
line therapies that will hopefully improve efficacy and toler-
ability in selected groups of melanoma patients.
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